scholarly journals Risk factors for second acute myeloid leukemia/myelodysplastic syndrome among survivors of non-Hodgkin lymphoma

Leukemia ◽  
2015 ◽  
Vol 30 (5) ◽  
pp. 1187-1190 ◽  
Author(s):  
C J K Lam ◽  
R E Curtis ◽  
G M Dores ◽  
E A Engels ◽  
N E Caporaso ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Hodgkin Lymphoma ◽  
Myeloid Leukemia ◽  
Non Hodgkin Lymphoma ◽  
Acute Myeloid

scholarly journals Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
M. Malagola ◽  
N. Polverelli ◽  
V. Cancelli ◽  
E. Morello ◽  
A. Turra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Clinical Risk Factors ◽  
Decision Algorithm ◽  
Platelet Recovery ◽  
Clinical Risk ◽  
History Of ◽  
Acute Myeloid

We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients.

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide

2005 ◽  
Vol 23 (18) ◽  
pp. 4179-4191 ◽  
Author(s):  
Claudio Praga ◽  
Jonas Bergh ◽  
Judith Bliss ◽  
Jacques Bonneterre ◽  
Bruno Cesana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Early Breast Cancer ◽  
Myeloid Leukemia ◽  
Lower Probability ◽  
Cumulative Probability ◽  
Secondary Leukemia ◽  
Acute Myeloid

Purpose We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Patients and Methods The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years). Cases of AML or MDS (AML/MDS) were reported, with disease characteristics. Incidence and cumulative risk were compared for possible risk factors, for assigned regimens, and for administered cumulative doses of epirubicin and cyclophosphamide. Results In 7,110 patients treated with epirubicin-containing regimens (92% of whom also received cyclophosphamide), 8-year cumulative probability of AML/MDS was 0.55% (95% CI, 0.33% to 0.78%). The risk of developing AML/MDS increased in relation to planned epirubicin dose per cycle, planned epirubicin dose-intensity, and administered cumulative doses of epirubicin and cyclophosphamide. Patients with administered cumulative doses of both epirubicin and cyclophosphamide not exceeding those used in standard regimens (≤ 720 mg/m2 and ≤ 6,300 mg/m2, respectively) had an 8-year cumulative probability of developing AML/MDS of 0.37% (95% CI, 0.13% to 0.61%) compared with 4.97% (95% CI, 2.06% to 7.87%) for patients administered higher cumulative doses of both epirubicin and cyclophosphamide. Conclusion Patients treated with standard cumulative doses of adjuvant epirubicin (≤ 720 mg/m2) and cyclophosphamide (≤ 6,300 mg/m2) for early breast cancer have a lower probability of secondary leukemia than patients treated with higher cumulative doses. Increased risk of secondary leukemia must be considered when assessing the potential benefit to risk ratio of higher than standard doses.

Sign in / Sign up

Export Citation Format

Share Document